Key takeaways:

HF with preserved ejection fraction is common among people with obesity and type 2 diabetes.

New real-world data suggest semaglutide and tirzepatide may reduce risk for HF hospitalization and mortality.

Results of a new study support using semaglutide and tirzepatide to reduce risk in patients with cardiometabolic heart failure with preserved ejection fraction.

The study investigated the effectiveness and safety of semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Mounjaro/Zepbound, Eli Lilly) in clinical practice among new users who had cardiometabolic HFpEF.

HF with preserved ejection fraction is common among people with obesity and type 2 diabetes. Image: Adobe Stock

“Patients who initiated semaglutide or tirzepatide had over a 40% lower risk of being hos

See Full Page